<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We aimed to study patients with splanchnic vein <z:mp ids='MP_0005048'>thrombosis</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>) and <z:hpo ids='HP_0005305'>cerebral vein thrombosis</z:hpo> (CVT) searching for JAK2 mutations </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated 14 patients (median age: 41.5 years) with portal vein <z:mp ids='MP_0005048'>thrombosis</z:mp> (PVT) = 7; mesenteric vein <z:mp ids='MP_0005048'>thrombosis</z:mp> (MVT) = 3; and CVT = 4 </plain></SENT>
<SENT sid="2" pm="."><plain>JAK2 V617F was assessed by allele specific PCR of peripheral blood DNA </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, DNA was sequenced for other JAK2 mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Other inherited and acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> risk factors were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>JAK2 V617F was positive in four out of seven patients with PVT and in one CVT patient </plain></SENT>
<SENT sid="6" pm="."><plain>These five patients had a diagnosis of myelo-proliferative disorder (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) at the moment of the occurrence of <z:mp ids='MP_0005048'>thrombosis</z:mp> (n = 2) or later (n = 2) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with MVT and CVT were negative for JAK2 V617F, except one patient with CVT and a diagnosis of <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>No other JAK2 mutations were found in this cohort </plain></SENT>
<SENT sid="9" pm="."><plain>Besides <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, other <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> risk factors were identified in five patients </plain></SENT>
<SENT sid="10" pm="."><plain>One patient had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> as well as <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> risk factor </plain></SENT>
<SENT sid="11" pm="."><plain>In this group, 4 out of 7 of the patients with PVT carried the JAK2 V617F mutation with or without overt <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>However, the investigation of other JAK2 mutations may not be necessary in patients with <z:mp ids='MP_0005048'>thrombosis</z:mp> at unusual sites </plain></SENT>
</text></document>